John Stone

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. ncbi Limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's granulomatosis etanercept trial
    John H Stone
    Johns Hopkins Vasculitis Center, 5501 Hopkins Bayview Circle, JHAAC 1B 23, Baltimore, MD 21223, USA
    Arthritis Rheum 48:2299-309. 2003
  2. ncbi Of ears and E-mails
    John H Stone
    Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA
    Ann Intern Med 141:241-2. 2004
  3. ncbi Human monocytic ehrlichiosis
    John H Stone
    Johns Hopkins Vasculitis Center, Division of Rheumatology, Johns Hopkins Bayview Medical Center, Baltimore, MD 21224, USA
    JAMA 292:2263-70. 2004
  4. ncbi Current status of tumor necrosis factor inhibition strategies in the treatment of vasculitis
    John H Stone
    Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Kidney Blood Press Res 26:240-8. 2003
  5. ncbi A serum proteomic approach to gauging the state of remission in Wegener's granulomatosis
    John H Stone
    The Johns Hopkins Vasculitis Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21224, USA
    Arthritis Rheum 52:902-10. 2005
  6. ncbi Polyarteritis nodosa
    John H Stone
    Division of Rheumatology, Johns Hopkins Vasculitis Center, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA
    JAMA 288:1632-9. 2002
  7. ncbi Hearing voices
    John H Stone
    Division of Rheumatology, Johns Hopkins Vasculitis Center, Baltimore, MD 21224, USA
    Pharos Alpha Omega Alpha Honor Med Soc 69:31-2. 2006
  8. ncbi Targeted therapies in systemic vasculitis
    John H Stone
    The Johns Hopkins Vasculitis Center, and Department of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA
    Cleve Clin J Med 69:SII124-8. 2002
  9. ncbi Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial
    John H Stone
    Johns Hopkins University, Baltimore, Maryland, USA
    Arthritis Rheum 54:1608-18. 2006
  10. ncbi Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET)
    Philip Seo
    Johns Hopkins University, Baltimore, Maryland
    Arthritis Rheum 52:2168-78. 2005

Research Grants

  1. Translational Research in Systemic Vasculitis
    John Stone; Fiscal Year: 2006

Detail Information

Publications40

  1. ncbi Limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's granulomatosis etanercept trial
    John H Stone
    Johns Hopkins Vasculitis Center, 5501 Hopkins Bayview Circle, JHAAC 1B 23, Baltimore, MD 21223, USA
    Arthritis Rheum 48:2299-309. 2003
    ..To report baseline data on 180 patients with Wegener's granulomatosis (WG) enrolled in the WG Etanercept Trial (WGET), and to examine demographic and clinical differences between patients with limited disease and those with severe disease...
  2. ncbi Of ears and E-mails
    John H Stone
    Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA
    Ann Intern Med 141:241-2. 2004
  3. ncbi Human monocytic ehrlichiosis
    John H Stone
    Johns Hopkins Vasculitis Center, Division of Rheumatology, Johns Hopkins Bayview Medical Center, Baltimore, MD 21224, USA
    JAMA 292:2263-70. 2004
    ..The patient improved promptly following institution of doxycycline, and his cardiac function returned to normal over a period of 4 months...
  4. ncbi Current status of tumor necrosis factor inhibition strategies in the treatment of vasculitis
    John H Stone
    Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Kidney Blood Press Res 26:240-8. 2003
  5. ncbi A serum proteomic approach to gauging the state of remission in Wegener's granulomatosis
    John H Stone
    The Johns Hopkins Vasculitis Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21224, USA
    Arthritis Rheum 52:902-10. 2005
    ..To identify serum ion patterns that distinguish remission from active disease in patients with Wegener's granulomatosis (WG)...
  6. ncbi Polyarteritis nodosa
    John H Stone
    Division of Rheumatology, Johns Hopkins Vasculitis Center, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA
    JAMA 288:1632-9. 2002
    ..He was ultimately able to discontinue all of his immunosuppressive medications. The case is discussed in the context of the first patient ever described with PAN, the classic report of Kussmaul and Maier...
  7. ncbi Hearing voices
    John H Stone
    Division of Rheumatology, Johns Hopkins Vasculitis Center, Baltimore, MD 21224, USA
    Pharos Alpha Omega Alpha Honor Med Soc 69:31-2. 2006
  8. ncbi Targeted therapies in systemic vasculitis
    John H Stone
    The Johns Hopkins Vasculitis Center, and Department of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA
    Cleve Clin J Med 69:SII124-8. 2002
  9. ncbi Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial
    John H Stone
    Johns Hopkins University, Baltimore, Maryland, USA
    Arthritis Rheum 54:1608-18. 2006
    ..This study was undertaken to further explore the potential association between anti-TNF therapy and the development of malignancy in these patients...
  10. ncbi Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET)
    Philip Seo
    Johns Hopkins University, Baltimore, Maryland
    Arthritis Rheum 52:2168-78. 2005
    ..An important measure of future therapeutic approaches will be their ability to reduce the damage accrued over time...
  11. ncbi The antineutrophil cytoplasmic antibody-associated vasculitides
    Philip Seo
    Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Am J Med 117:39-50. 2004
    ..This review describes the clinical and pathologic hallmarks of the ANCA-associated vasculitides, discusses the role of ANCA assays in diagnosis and treatment, and outlines an approach to the evaluation and management of these diseases...
  12. ncbi Metalloproteinase-2 and -9 in giant cell arteritis: involvement in vascular remodeling
    Alicia Rodriguez-Pla
    Department of Medicine, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Circulation 112:264-9. 2005
    ..Understanding the specific mediators of arterial damage in GCA could lead to new therapeutic targets in this disease...
  13. ncbi Correlation of percentage of normal glomeruli with renal outcome in Wegener's granulomatosis
    Melanie K Haroun
    Division of Nephrology, The Johns Hopkins Vasculitis Center, Department of Medicine, Baltimore, MD 21205, USA
    Am J Nephrol 22:497-503. 2002
    ..We examined the correlations between renal biopsy findings in Wegener's granulomatosis and renal function at baseline and 1 year in 22 patients who presented between 1988 and 1999...
  14. ncbi Domains of health-related quality of life important to patients with giant cell arteritis
    David B Hellmann
    Johns Hopkins University School of Medicine, Hopkins Bayview Medical Center, 4940 Eastern Avenue, Baltimore, MD 21224, USA
    Arthritis Rheum 49:819-25. 2003
    ..To determine aspects of quality of life (QOL) important to people with giant cell arteritis (GCA)...
  15. ncbi No detection of parvovirus B19 or herpesvirus DNA in giant cell arteritis
    Alicia Rodriguez-Pla
    Pediatrics Department, Stanley Division of Developmental Neurovirology, Johns Hopkins University, Baltimore, MD 21287 4933, USA
    J Clin Virol 31:11-5. 2004
    ..Compelling arguments exist for a role of infectious agent in giant cell arteritis (GCA). Parvovirus B19 and several herpesviruses have focussed the attention in recent years, but the few studies to date have yielded inconsistent results...
  16. ncbi Herpes zoster in immunocompromised patients: incidence, timing, and risk factors
    Peter K Wung
    Johns Hopkins University School of Medicine, Johns Hopkins University, Baltimore, MD, USA
    Am J Med 118:1416. 2005
    ..These data may inform studies of interventions designed to prevent herpes zoster in patients on treatment for immune-mediated diseases...
  17. ncbi Temporal arteritis and Chlamydia pneumoniae: failure to detect the organism by polymerase chain reaction in ninety cases and ninety controls
    Michael J Regan
    Johns Hopkins University, Baltimore, Maryland, USA
    Arthritis Rheum 46:1056-60. 2002
    ..CONCLUSION: The results of this study using sensitive and specific PCR analyses do not support a role for C pneumoniae in the pathogenesis of TA...
  18. ncbi Microscopic polyangiitis presenting as a "pulmonary-muscle" syndrome: is subclinical alveolar hemorrhage the mechanism of pulmonary fibrosis?
    Julius Birnbaum
    Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Arthritis Rheum 56:2065-71. 2007
    ..The histologic findings in this case implicate subclinical episodes of alveolar hemorrhage as the mechanism of interstitial lung disease in MPA...
  19. ncbi Small-vessel and medium-vessel vasculitis
    Philip Seo
    Johns Hopkins University and The Johns Hopkins Vasculitis Center, Baltimore, Maryland, USA
    Arthritis Rheum 57:1552-9. 2007
  20. ncbi Therapeutics of Wegener's granulomatosis
    Peter K Wung
    Johns Hopkins Bayview Medical Center, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA
    Nat Clin Pract Rheumatol 2:192-200. 2006
    ..Severe toxicity associated with the available agents and, therefore, there is keen interest in the development of alternative treatment strategies for this disease...
  21. ncbi Effects of glucocorticoids on weight change during the treatment of Wegener's granulomatosis
    Peter K Wung
    Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Arthritis Rheum 59:746-53. 2008
    ..Weight gain is a side effect of glucocorticoid (GC) use, but the natural history and health implications of changes in weight that occur during the treatment of inflammatory disease are not understood...
  22. ncbi Communication between physicians and patients in the era of E-medicine
    John H Stone
    Vasculitis Center and Johns Hopkins University School of Medicine, Baltimore, USA
    N Engl J Med 356:2451-4. 2007
  23. ncbi The future of damage assessment in vasculitis
    Philip Seo
    Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    J Rheumatol 34:1357-71. 2007
    ..This initiative is part of a larger international effort to create a unified approach to disease assessment for the primary systemic vasculitides...
  24. ncbi Incidentalomas--clinical correlation and translational science required
    John H Stone
    Johns Hopkins University School of Medicine, Baltimore, USA
    N Engl J Med 354:2748-9. 2006
  25. ncbi Churg-Strauss syndrome presenting with salivary gland enlargement and respiratory distress
    Francesco Boin
    Vasculitis Center, The Johns Hopkins University School of Medicine, 5501 Hopkins Bayview Circle 1B.23, Baltimore, MD 21224, USA
    Arthritis Rheum 55:167-70. 2006
  26. ncbi Vasculitis and systemic infections
    Alicia Rodriguez-Pla
    Division of Molecular and Clinical Rheumatology, The Johns Hopkins School of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21224, USA
    Curr Opin Rheumatol 18:39-47. 2006
    ..We review the principal pathogenic mechanisms that have been implicated for possible roles in the vascular inflammation initiated by infectious agents. We also summarize the most important literature related to this topic...
  27. ncbi Gastrointestinal involvement in polyarteritis nodosa (1986-2000): presentation and outcomes in 24 patients
    Stuart M Levine
    Division of Rheumatology, Department of Medicine, The Johns Hopkins Vasculitis Center, Johns Hopkins University, 1830 E. Monument Street, Baltimore, MD 21205, USA
    Am J Med 112:386-91. 2002
    ..Compared with a historical cohort at our institution, mortality from this complication may have decreased, perhaps because of earlier diagnosis...
  28. ncbi Classification and diagnostic criteria in systemic vasculitis
    Assil Saleh
    The Johns Hopkins Vasculitis Center, 5501 Hopkins Bayview Circle, 1B.23, Baltimore, MD 21224, USA
    Best Pract Res Clin Rheumatol 19:209-21. 2005
    ..The Chapel Hill Consensus Conference has clarified some existing controversies in nomenclature of the systemic vasculitides. Robust diagnostic criteria for the various forms of vasculitis have, however, remained elusive...
  29. ncbi Large-vessel vasculitis
    Philip Seo
    Johns Hopkins University, Baltimore, MD 21224, USA
    Arthritis Rheum 51:128-39. 2004
  30. ncbi Vasculitis: a collection of pearls and myths
    John H Stone
    Rheumatology Unit, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA
    Rheum Dis Clin North Am 33:691-739, v. 2007
    ..Over time, numerous myths and occasional pearls have arisen from the care of patients with these disorders. This collection of pearls and myths gathers lessons about the status of clinical care of vasculitis patients in the year 2008...
  31. ncbi Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis
    Karina A Keogh
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Arthritis Rheum 52:262-8. 2005
    ....
  32. ncbi Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial
    Gary S Hoffman
    Center for Vasculitis Care and Research, The Cleveland Clinic Foundation, Lerner College of Medicine, Cleveland, Ohio 44195, USA
    Ann Intern Med 146:621-30. 2007
    ..Tumor necrosis factor-alpha is present in arteries in giant cell arteritis...
  33. ncbi Randomized controlled trials in vasculitis associated with anti-neutrophil cytoplasmic antibodies
    Oemer N Goek
    The University of Heidelberg
    Curr Opin Rheumatol 17:257-64. 2005
    ....
  34. ncbi Implications of antineutrophil cytoplasmic antibody status when switching to maintenance therapy
    Gary S Hoffman
    Arthritis Rheum 53:1-2. 2005
  35. ncbi Methotrexate in polymyalgia rheumatica: kernel of truth or curse of Tantalus?
    John H Stone
    Ann Intern Med 141:568-9. 2004
  36. ncbi ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis
    Javier D Finkielman
    Thoracic Disease Research Unit, Division of Pulmonary and Critical Care Medicine, Mayo Clinic and Foundation, Rochester, Minn 55905, USA
    Am J Med 120:643.e9-14. 2007
    ..The objective of this study was to determine the frequency of ANCA in patients with active Wegener's granulomatosis and to assess the influence of disease severity on test results...
  37. ncbi Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis
    Javier D Finkielman
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Ann Intern Med 147:611-9. 2007
    ..The utility of antineutrophil cytoplasmic antibody (ANCA) levels to guide the management of patients with Wegener granulomatosis remains controversial...
  38. ncbi Antiendothelial cell antibodies in patients with Wegener's granulomatosis: prevalence and correlation with disease activity and manifestations
    Jodi K Sebastian
    Boston University, Boston, Massachusetts 02118, USA
    J Rheumatol 34:1027-31. 2007
    ..We examined a large, well-characterized cohort of patients with WG and active disease for the presence of AECA...
  39. ncbi A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis
    Gary S Hoffman
    Cleveland Clinic Foundation, Cleveland, Ohio 44915, USA
    Arthritis Rheum 46:1309-18. 2002
    ....
  40. ncbi Assessment of the item selection and weighting in the Birmingham vasculitis activity score for Wegener's granulomatosis
    Alfred D Mahr
    Boston University, Boston, Massachusetts 02118, USA
    Arthritis Rheum 59:884-91. 2008
    ..To assess the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) with respect to its selection and weighting of items...

Research Grants1

  1. Translational Research in Systemic Vasculitis
    John Stone; Fiscal Year: 2006
    ..Insights derived from this translational research program described by Dr. John Stone, Director of the Johns Hopkins Vasculitis Center, may lead to novel methods of evaluating vasculitis patients...